Podcasts about mbbs

Deep Chandh Raja, MBBS, MD, PhD, Australian National University, Kauvery Hospital is joined by Andreas Pflaumer, MD, FHRS, CEPS-P, Royal Children's Hospital Melbourne and Maully J. Shah, MBBS, FHRS, CCDS, CEPS-P Children's Hospital of Philadelphia, to discuss the unmet clinical need for a smaller pacemaker suitable for neonates and infants, researchers developed a specially modified implantable pulse generator incorporating a Medtronic Micra subassembly within a polymer header, connected to a bipolar epicardial lead. This study aimed to evaluate the safety, feasibility, and midterm outcomes of this novel device, reporting follow-up data from multiple centers on patients who underwent implantation. https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCEP.124.013436?doi=10.1161/CIRCEP.124.013436 Host Disclosure(s): D. Raja:  Nothing to disclose. Contributor Disclosure(s): M. Shah: Honoraria/Speaking/Consulting: Medtronic, IBHRE Abbott, BioTelemetry, Boston Scientific, Kardium Other Financial Relationships: American College of Cardiology A. Pflaumer: Stock Options - Privately Held: Navi Medical Systems Officer, Trustee, Director, Committee Chair: PACES, Asia Pacific Heart Rhythm Society (APHRS)

What Is Virg*nity? | Dr. Gorakh Mandrupkar & Mukta Chaitanya | Khuspus with Omkar #amuktamukअमुकतमुक ला subscribe करण्यासाठी click करा: https://youtube.com/@amuktamuk?si=LCVcdLVB9KMPVHrkVirg*nity म्हणजे काय? Hymen Break होणं म्हणजे काय? Menstrual cups वापरल्या नंतर Virg*nity Break होते का? पुरुषांना Virg*nity विचारली जात नाही का? Virg*nity ला स्त्रीच्या पावित्र्याशी जोडणं योग्य आहे का? अजूनही लग्न करतांना या गोष्टीचा विचार केला जातो का? पालक म्हणून मुलांना याबाबत कश्या पद्धतीने शिक्षण दिलं पाहिजे?या विषयावर आपण डॉ.गोरख मंद्रुपकर (MBBS, DGO, FCPS,FICOG,स्त्री रोग आणि IVF तज्ञ,मंद्रूपकर क्लिनिक, इस्लामपूर) आणि मुक्ता चैतन्य (Writer, Journalist) यांच्यासोबत खुसपुस केली आहे पूर्ण एपिसोड नक्की बघा.What is virg*nity? What does the breaking of the hymen mean? Does using a menstrual cup result in the loss of virg*nity? Why is virg*nity not questioned for men? Is it appropriate to associate a woman's virg*nity with her purity? Is this still considered when getting married? As parents, how should we educate our children about this topic?We had an insightful conversation on this subject with Dr. Gorakh Mandrupkar (MBBS, DGO, FCPS, FICOG, Obstetrician & IVF Specialist, Mandrupkar Clinic, Islampur) and Mukti Chaitanya (Writer & Journalist). Watch the full episode for the complete discussion.आणि मित्रांनो आपलं Merch घेण्यासाठी लगेच click करा! Amuktamuk.swiftindi.comDisclaimer: व्हिडिओमध्ये किंवा आमच्या कोणत्याही चॅनेलवर पॅनलिस्ट/अतिथी/होस्टद्वारे सांगण्यात आलेली कोणतीही माहिती केवळ general information साठी आहे. पॉडकास्ट दरम्यान किंवा त्यासंबंधात व्यक्त केलेली कोणतीही मते निर्माते/कंपनी/चॅनल किंवा त्यांच्या कोणत्याही कर्मचाऱ्यांची मते/अभिव्यक्ती/विचार दर्शवत नाहीत.अतिथींनी केलेली विधाने सद्भावनेने आणि चांगल्या हेतूने केलेली आहेत ती विश्वास ठेवण्याजोगी आहेत किंवा ती सत्य आणि वस्तुस्थितीनुसार सत्य मानण्याचे कारण आहे. चॅनलने सादर केलेला सध्याचा व्हिडिओ केवळ माहिती आणि मनोरंजनाच्या उद्देशाने आहे आणि चॅनल त्याची अचूकता आणि वैधता यासाठी कोणतीही जबाबदारी घेत नाही.अतिथींनी किंवा पॉडकास्ट दरम्यान व्यक्त केलेली कोणतीही माहिती किंवा विचार व्यक्ती/कास्ट/समुदाय/वंश/धर्म यांच्या भावना दुखावण्याचा किंवा कोणत्याही संस्था/राजकीय पक्ष/राजकारणी/नेत्याचा, जिवंत किंवा मृत यांचा अपमान करण्याचा हेतू नाही.. Guests: Dr. Gorakh Mandrupkar (MBBS, DGO, FCPS, FICOG, Obstetrician & IVF Specialist, Mandrupkar Clinic, Islampur), Mukta Chaitanya, Writer and Journalist.Host: Omkar Jadhav.Creative Producer: Shardul Kadam.Editor: Rohit Landge.Edit Assistant: Rameshwar Garkal.Content Manager: Sohan Mane.Social Media Manager: Sonali Gokhale.Legal Advisor: Savani Vaze.Business Development Executive: Sai Kher.Intern: Mrunal Arve.About The Host Omkar Jadhav.Co-founder – Amuk Tamuk Podcast NetworkPodcast Host | Writer | Director | Actor | YouTube & Podcast ConsultantWith 8+ years in digital content, former Content & Programming Head at BhaDiPa & Vishay Khol.Directed 100+ sketches, 3 web series & non-fiction shows including Aai & Me, Jhoom, 9 to 5, Oddvata.Creative Producer – BErojgaar | Asst. Director – The Kerala StoryHost of Khuspus – a podcast on taboo and uncomfortable topics.Visiting Faculty – Ranade Institute, Pune University.Connect with us: Twitter: https://twitter.com/amuk_tamukInstagram: https://www.instagram.com/amuktamuk/Facebook: https://www.facebook.com/amuktamukpodcastsSpotify: Khuspus #AmukTamuk #marathipodcasts

Giuseppe Tarantini, MD, PhD and Mirza Umair Khalid, MBBS, MD, FACC discuss the Coronary Access After TAVI (CAvEAT) Study.

Divaka Perera, MD and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the SERIAL study, the first randomized comparison of Fractional Flow Reserve and Instantaneous Wave Free Ratio in serial coronary artery disease.

Mehdi H. Shishehbor, DO, MPH, PhD, FACC and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the analysis of 1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.

Giuseppe Tarantini, MD, PhD and Mirza Umair Khalid, MBBS, MD, FACC discuss the Coronary Access After TAVI (CAvEAT) Study.

Mehdi H. Shishehbor, DO, MPH, PhD, FACC and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the analysis of 1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.

Divaka Perera, MD and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the SERIAL study, the first randomized comparison of Fractional Flow Reserve and Instantaneous Wave Free Ratio in serial coronary artery disease.

During a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a rich panel on mutation loss, minimal residual disease, and transplant timing.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD CME information and select publications

At the 2025 Kidney Cancer Research Summit hosted by KidneyCAN, CancerNetwork® spoke with a variety of leading experts about key developments in the research and management of kidney cancer. Throughout the meeting, presenters shared their findings related to updated clinical trial results, personalized cancer vaccines, potential biomarkers of interest, and other advancements in the field. Thomas Powles, MBBS, MCRP, MD, discussed outcomes from a quality-adjusted survival time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITESPARK-005 trial (NCT04195750), in which investigators evaluated treatment with belzutifan (Welireg) vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC). Powles, a professor of genitourinary oncology, lead for Solid Tumor Research, and director of Barts Cancer Institute at St. Bartholomew's Hospital, Queen Mary University of London, stated that these data demonstrate how belzutifan is more active and better tolerated than everolimus in this patient population. David A. Braun, MD, PhD, assistant professor at Yale School of Medicine and member of the Center of Molecular and Cellular Oncology within the Yale Cancer Center, detailed his presentation on a personalized neoantigen cancer vaccine as a treatment for those with RCC. Based on his presentation, Braun highlighted how neoantigen vaccines may effectively yield T-cell responses in patients, illustrating a need for additional, larger studies to elucidate the clinical activity of this modality in an adjuvant setting. Additionally, Wenxin (Vincent) Xu, MD, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, spoke about his presentation on how kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker of response to therapy in patients with RCC. His research posed questions on how KIM-1 can inform the use of adjuvant therapy or specific therapeutic combinations like nivolumab (Opdivo) plus ipilimumab (Yervoy) for this patient population. Eric Jonasch, MD, gave an overview of his presentation focused on the Kidney Cancer Research Consortium, a research partnership spanning 7 institutions dedicated to facilitating mechanistic, hypothesis-testing clinical trials in RCC. Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, described how this collaboration aims to link identifiable biological characteristics of RCC subtypes to specific treatment strategies while developing predictive biomarkers. KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. You can learn more about KidneyCAN's work here: https://kidneycan.org/ References 1. Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. Abstract 13. 2. Braun DA. Personalized vaccines in kidney cancer: a journey from concept to clinic. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 3. Xu W. From bench to bedside: advancing KIM-1 as a tool for clinical decision-making. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 4. Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

In episode eighteen, PeDRA Pub Club host Hannah Chang and guest panelists, Bella Plumptre, MBBS, and Cheryl Bayart, MD, discuss the article How issues of autonomy and consent differ between children and adults: Kids are not just little people, published in Clinical Dermatology in 2017.PeDRA and the greater pediatric dermatology community are deeply saddened by the sudden passing of Dr. Robert Sidbury. To donate in his honor, please visit the SPD Foundation.

Sign up to Easy Ayurveda Video Classes by clicking the link belowhttps://www.easyayurveda.com/video-classes/Video Course: “Ayurvedic food and Nutrition”https://www.easyayurveda.com/nutrition/Buy Tridosha Made Easy Bookhttps://www.easyayurveda.com/tridosha-made-easy-3/Buy Tridosha Made Easy Book in Spanish LanguageEl corazón de los doshas: Nuevo librohttps://www.easyayurveda.com/el-corazon-de-los-doshas/Click to know more about Easy Ayurveda Hospitalhttps://www.easyayurveda.com/hospital/Buy our new course on Marma Therapy Part 1https://www.easyayurveda.com/marma1Buy our new course on Marma Therapy Part 1Subscribe to Easy Ayurveda Video Classes https://www.easyayurveda.com/video-classes/Subscribe to our free Easy Ayurveda newsletter here (you can unsubscribe and stop them anytime) -  https://forms.aweber.com/form/58/2129766958.htm Buy our course on diabetes reversal, powered by Madhavbaug https://www.easyayurveda.com/diabetes Buy our online video course on Treatment of cardiac disorders with Ayurveda https://www.easyayurveda.com/heartMaster ECG in one week. Sign up for video course https://www.easyayurveda.com/ecgContact Dr. MB Gururaja BAMS MD (Ayu)https://www.easyayurveda.com/gururaja  Contact Dr. Raghuram YS BAMS MD (Ayu)https://www.easyayurveda.com/raghuram Buy Easy Ayurveda Ebooks https://www.easyayurveda.com/my-book Buy Easy Ayurveda Printed Books https://www.easyayurveda.com/books/

Guest Suggestion Form: ⁠⁠https://forms.gle/bnaeY3FpoFU9ZjA47⁠⁠Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are her personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices.Order 'Build, Don't Talk' (in English) here: ⁠⁠https://amzn.eu/d/eCfijRu⁠⁠Order 'Build Don't Talk' (in Hindi) here: ⁠⁠https://amzn.eu/d/4wZISO0⁠⁠Follow Our Whatsapp Channel: ⁠⁠https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2J⁠⁠Subscribe To Our Other YouTube Channels:-⁠⁠https://www.youtube.com/@rajshamaniclips⁠⁠⁠⁠https://www.youtube.com/@RajShamani.Shorts⁠⁠

Please join host Jason T. Jacobson, MD, FHRS at HRS 2025 in San Diego as he discusses this article with Marmar Vaseghi, MD, MS, PhD, FHRS and Maynak Sardana, MBBS, MS. The prospective, multicenter, randomized BRAVE trial evaluated epicardial catheter ablation targeting the arrhythmogenic substrate in Brugada syndrome patients with implantable cardioverter-defibrillators (ICDs) to prevent ventricular fibrillation (VF). After a planned interim analysis of 52 patients, ablation significantly reduced VF episodes compared with controls (hazard ratio 0.29; P = .018), prompting early trial termination—approximately 83% remained VF-free after one procedure and 90% after a repeat, with a low complication rate (one hemopericardium). https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02381-1/fulltext?uuid=uuid%3A6285a37b-899f-4fcb-bab8-f79564e1bd57 Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting: Zoll Medical, Abbott Medical, Vektor Medical Stocks, Privately Held: Atlas 5D Research: CardioFocus, Inc. Contributor Disclosure(s): M. Vaseghi: Honoraria/Speaking/Consulting: Medtronic Inc., Zoll Inc. Stock Options, Privately Held: NeuCures, Anumana M. Sardana: Nothing to disclose.

Uncover the diverse scope of practice available in pediatric radiology. Shannon Farmakis, MD, speaks with host Raisa Amiruddin, MBBS, on the often unseen professional opportunities in pediatric imaging, including insights into the routines and realities of private practice and approaches for navigating a fulfilling career in the specialty. https://www.ajronline.org/doi/10.2214/AJR.25.33521

Sign up to Easy Ayurveda Video Classes by clicking the link belowhttps://www.easyayurveda.com/video-classes/Video Course: “Ayurvedic food and Nutrition”https://www.easyayurveda.com/nutrition/Buy Tridosha Made Easy Bookhttps://www.easyayurveda.com/tridosha-made-easy-3/Buy Tridosha Made Easy Book in Spanish LanguageEl corazón de los doshas: Nuevo librohttps://www.easyayurveda.com/el-corazon-de-los-doshas/Click to know more about Easy Ayurveda Hospitalhttps://www.easyayurveda.com/hospital/Buy our new course on Marma Therapy Part 1https://www.easyayurveda.com/marma1Buy our new course on Marma Therapy Part 1Subscribe to Easy Ayurveda Video Classes https://www.easyayurveda.com/video-classes/Subscribe to our free Easy Ayurveda newsletter here (you can unsubscribe and stop them anytime) -  https://forms.aweber.com/form/58/2129766958.htm Buy our course on diabetes reversal, powered by Madhavbaug https://www.easyayurveda.com/diabetes Buy our online video course on Treatment of cardiac disorders with Ayurveda https://www.easyayurveda.com/heartMaster ECG in one week. Sign up for video course https://www.easyayurveda.com/ecgContact Dr. MB Gururaja BAMS MD (Ayu)https://www.easyayurveda.com/gururaja  Contact Dr. Raghuram YS BAMS MD (Ayu)https://www.easyayurveda.com/raghuram Buy Easy Ayurveda Ebooks https://www.easyayurveda.com/my-book Buy Easy Ayurveda Printed Books https://www.easyayurveda.com/books/

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/44ySoL3Follow along with the slides: https://bit.ly/3IvwQrjGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/4lKaO2HFollow along with the slides: https://bit.ly/44PPBysGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Please visit answersincme.com/WHF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss how the latest therapeutic advances in frontline management of urothelial carcinoma can be integrated into practice to optimize patient care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the first-line treatment of advanced UC; Identify multidisciplinary strategies to optimize first-line treatment of patients with advanced UC; and Outline current and evolving multidisciplinary approaches to enhance outcomes for patients with UC.

Normal pressure hydrocephalus (NPH) is a clinical syndrome characterized by the triad of gait apraxia, cognitive impairment, and bladder dysfunction in the radiographic context of ventriculomegaly and normal intracranial pressure. Accurate diagnosis requires consideration of clinical and imaging signs, complemented by tests to exclude common mimics. In this episode, Lyell Jones, MD, FAAN speaks with Abhay R. Moghekar, MBBS, author of the article “Clinical Features and Diagnosis of Normal Pressure Hydrocephalus” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Moghekar is an associate professor of neurology at Johns Hopkins University School of Medicine in Baltimore, Maryland. Additional Resources Read the article: Clinical Features and Diagnosis of Normal Pressure Hydrocephalus Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today I'm interviewing Dr Abhay Moghekar, who recently authored an article on the clinical features and diagnosis of normal pressure hydrocephalus for our first-ever issue of Continuum dedicated to disorders of CSF dynamics. Dr Moghekar is an associate professor of neurology and the research director of the Cerebrospinal Fluid Center at Johns Hopkins University in Baltimore, Maryland. Dr Moghekar, welcome, and thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Moghekar: Thank you, Dr Jones. I'm Abhay Moghekar. I'm a neurologist at Hopkins, and I specialize in seeing patients with CSF disorders, of which normal pressure hydrocephalus happens to be the most common. Dr Jones: And let's get right to it. I think most of our listeners who are neurologists in practice have encountered normal pressure hydrocephalus, or NPH; and it's a challenging disorder for all the reasons that you outline in your really outstanding article. If you were going to think of one single most important message to our listeners about recognizing patients with NPH, what would that be? Dr Moghekar: I think I would say there are two important messages. One is that the triad is not sufficient to make the diagnosis, and the triad is not necessary to make the diagnosis. You know these three elements of the triad: cognitive problems, gait problems, bladder control problems are so common in the elderly that if you pick 10 people out in the community that have this triad, it's unlikely that even one of them has true NPH. On the other hand, you don't need all three elements of the triad to make the diagnosis because the order of symptoms matters. Often patients develop gait dysfunction first, then cognitive dysfunction, and then urinary incontinence. If you wait for all three elements of the triad to be present, it may be too late to offer them any clear benefit. And hence, you know, it's neither sufficient nor necessary to make the diagnosis. Dr Jones: That's a really great point. I think most of our listeners are familiar with the fact that, you know, we're taught these classic triads or pentads or whatever, and they're rarely all present. In a way, it's maybe a useful prompt, but it could be distracting or misleading, even in a way, in terms of recognizing the patient. So what clues do you use, Dr Moghekar, to really think that a patient may have NPH? Dr Moghekar: So, there are two important aspects about gait dysfunction. Say somebody comes in with all three elements of the triad. You want to know two things. Which came first? If gate impairment precedes cognitive impairment, it's still very likely that NPH is in the differential. And of the two, which are more- relatively more affected? So, if somebody has very severe dementia and they have a little bit of gait problems, NPH is not as likely. So, is gait affected earlier than cognitive dysfunction, and is it affected to a more severe degree than cognitive dysfunction? And those two things clue me in to the possibility of NPH. You still obviously need to get imaging to make sure that they have large ventricles. One of the problems with imaging is large ventricles are present in so many different patients. Normal aging causes large ventricles. Obviously, many neurodegenerative disorders because of cerebral atrophy will cause large ventricles. And there's an often-used metric called as the events index, which is the ratio of the bitemporal horns- of the frontal horns of the lateral ventricles compared to the maximum diameter of the skull at that level. And if that ratio is more than 0.3, it's often used as a de facto measure of ventriculomegaly. What we've increasingly realized is that this ratio changes with age. And there's an excellent study that used the ADNI database that looked at how this ratio changes by age and sex. So, in fact, we now know that an 85-year-old woman who has an events index of 0.37 which would be considered ventriculomegaly is actually normal for age and sex. So, we need to start adopting these more modern age- and sex-appropriate age cutoffs of ventriculomegaly so as not to overcall everybody with big ventricles as having possible NPH. Dr Jones: That's very helpful. And I do want to come back to this challenge that we've seen in our field of overdiagnosis and underdiagnosis. But I think most of us are familiar with the concept of how hydrocephalus could cause neurologic deficits. But what's the latest on the mechanism of NPH? Why do some patients get this and others don't? Dr Moghekar: Very good question. I don't think we know for sure. And it for a long time we thought it was a plumbing issue. Right? And that's why shunts work. People thought it was impaired CSF absorption, but multiple studies have shown that not to be true. It's likely a combination of impaired cerebral blood flow, biomechanical factors like compliance, and even congenital factors that play a role in the pathogenesis of NPH. And yes, while putting in shunts likely drains CSF, putting in a shunt also definitely changes the compliance of the brain and affects blood flow to the subcortical regions of the brain. So, there are likely multiple mechanisms by which shunts benefit, and hence it's very likely that there's no single explanation for the pathogenesis of NPH. Dr Jones: We explored this in a recent Continuum issue on dementia. Many patients who have cognitive impairment have co-pathologies, multiple different causes. I was interested to read in your article about the genetic risk profile for NPH. It's not something I'd ever really considered in a disorder that is predominantly seen in older patients. Tell us a little more about those genetic risks. Dr Moghekar: Yeah, everyone is aware of the role genetics plays in congenital hydrocephalus, but until recently we were not aware that certain genetic factors may also be relevant to adult-onset normal pressure hydrocephalus. We've suspected this for a long time because nearly half of our patients who come to us to see us in clinic with NPH have head circumferences that are more than 90th percentile for height. And you know, that clearly indicates that this started shortly at the time after birth or soon afterwards. So, we've suspected for a long time that genetic factors play a role, but for a long time there were not enough large studies or well-conducted studies. But recently studies out of Japan and the US have shown mutations in genes like CF43 and CWH43 are disproportionately increased in patients with NPH. So, we are discovering increasingly that there are genetic factors that underlie even adult onset in patients. There are many more waiting to be discovered. Dr Jones: Really fascinating. And obviously getting more insight into the risk and mechanisms would be helpful in identifying these patients potentially earlier. And another thing that I learned in your article that I thought was really interesting, and maybe you can tell us more about it, is the association between normal pressure hydrocephalus and the observation of cervical spinal stenosis, many of whom require decompression. What's behind that association, do you think? Dr Moghekar: That's a very interesting study that was actually done at your institution, at Mayo Clinic, that showed this association. You know, as we all get older, you know, the incidence of cervical stenosis due to osteoarthritis goes up, but the incidence of significant, clinically significant cervical stenosis in the NPH population was much higher than what we would have expected. Whether this is merely an association in a vulnerable population or is it actually causal is not known and will need further study. Dr Jones: It's interesting to speculate, does that stenosis affect the flow of CSF and somehow predispose to a- again, maybe a partial degree for some patients? Dr Moghekar: Yeah, which goes back to the possible hydrodynamic theory of normal pressure hydrocephalus; you know, if it's obstructing normal CSF flow, you know, are the hydrodynamics affected in the brain that in turn could lead to the development of hydrocephalus. Dr Jones: One of the things I really enjoyed about your article, Abhay, was the very strong clinical focus, right? We can't just take an isolated biomarker or radiographic feature and rely on that, right? We really do need to have clinical suspicion, clinical judgment. And I think most of our listeners who've been in practice are familiar with the use and the importance of the large-volume lumbar puncture to determine who may have, and by exclusion not have, NPH, and then who might respond to CSF diversion. And I think those of us who have been in this situation are also familiar with the scenario where you think someone may have NPH and you do a large-volume lumbar puncture and they feel better, but you can't objectively see a difference. How do you make that test useful and objective in your practice? What do you do? Dr Moghekar: Yeah, it's a huge challenge in getting this objective assessment done carefully because you have to remember, you know, subconsciously you're telling the patients, I think you have NPH. I'm going to do this spinal tap, and if you walk better afterwards, you're going to get a shunt and you're going to be cured. And you can imagine the huge placebo response that can elicit in our subjects. So, we always like to see, definitely, did the patient subjectively feel better? Because yes, that's an important metric to consider because we want them to feel better. But we also wanted to be grounded in objective truths. And for that, we need to do different tests of speed, balance and endurance. Not everyone has the resources to do this, but I think it's important to test different domains. Just like for cognition, you know, we just don't test memory, right? We test executive function, language, visuospatial function. Similarly, walking is not just walking, right? It's gait speed, it's balance, and it's endurance. So, you need to ideally test at least most of these different domains for gait and you need to have some kind of clear criteria as to how are you going to define improvement. You know, is a 5% improvement, is a 10% improvement in gait, enough? Is 20%? Where is that cutoff? And as a field, we've not done a great job of coming up with standardized criteria for this. And it varies currently, the practice varies quite significantly from center to center at the current time. Dr Jones: So, one of the nice things you had in your article was helpful tips to be objective if you're in a lower-resource setting. For you, this isn't a common scenario that someone encounters in their practice as opposed to a center that maybe does a large volume of these. What are some relatively straightforward objective measures that a neurologist or someone else might use to determine if someone is improving after a large-volume LP? Dr Moghekar: Yeah, excellent question, Dr Jones, and very practically relevant too. So, you need to at least assess two of the domains that are most affected. One is speed and one is balance. You know, these patients fall ultimately, right, if you don't treat them correctly. In terms of speed, there are two very simple tests that anybody can do within a couple of minutes. One is the timed “up-and-go” test. It's a test that's even recommended by the CDC. It correlates very well with faults and disability and it can be done in any clinic. You just need about ten feet of space and a chair and a stopwatch, and it takes about a minute or slightly more to do that test. And there are objective age-associated norms for the timed up-and-go test, so it's easy to know if your patient is normal or not. The same thing goes for the 10-meter walk test. You do need a slightly longer walkway, but it's a fairly easy and well-standardized test. So, you can do one of those two; you don't need to do both of them. And for balance, you can do the 30-second “sit-to-stand”; and it's literally, again, 30 seconds. You need a chair, and you need somebody to watch the patient and see how many times they can sit up and stand up from a seated position. Then again, good normative data for that. If you want to be a little more sophisticated, you can do the 4-stage balance test. So, I think these are tests that don't add too much time to your daily assessment and can be done with even trained medical assistants in any clinic. And you don't need a trained physical therapist to do these assessments. Dr Jones: Very practical. And again, something that is pretty easily deployed, something we do before and then after the LP. I did see you mentioned in your article the dual timed up-and-go test where it's a simultaneous gait and executive function test. And I've got to be honest with you, Dr Moghekar, I was a little worried if I would pass that test, but that may be beyond the scope of our time today. Actually, how do you do that? How do you do the simultaneous cognitive assessment? Dr Moghekar: So, we asked them to count back from 100, subtracting 3. And we do it particularly in patients who are mildly impaired right? So, if they're already walking really good, but then you give them a cognitive stressor, you know, that will slow them down. So, we reserve it for patients who are high-performing. Dr Jones: That's fantastic. I'm probably aging myself a little here. I have noticed in my career, a little bit of a pendulum swing in terms of the recognition or acceptance of the prevalence of normal pressure hydrocephalus. I recall when I was a resident, many, many people that we saw in clinic had normal pressure hydrocephalus. Then it seemed for a while that it really faded into the background and was much less discussed and much less recognized and diagnosed, and less treated. And now that pendulum seems to have swung back the other way. What's behind that from your perspective? Dr Moghekar: It's an interesting backstory to all of this. When the first article about NPH was published in the Newman Journal of Medicine, it was actually a combined article with both neurologists and neurosurgeons on it. They did describe it as a treatable dementia. And what that did is it opened up the floodgates so that everybody with any kind of dementia started getting shunts left, right, and center. And back then, shunts were not programmable. There were no antibiotic impregnated catheters. So, the incidence of subdural hematomas and shunt-related infections was very high. In fact, one of our esteemed neurologists back then, Houston Merritt, wrote a scathing editorial that Victor and Adam should lose their professorships for writing such an article because the outcomes of these patients were so bad. So, for a very long period of time, neurologists stopped seeing these patients and stopped believing in NPH as a separate entity. And it became the domain of neurosurgeons for over two or three decades, until more recently when randomized trials started being done early on out of Europe. And now there's a big NIH study going on in the US, and these studies showed, in fact, that NPH exists as a true, distinct entity. And finally, neurologists have started getting more interested in the science and understanding the pathophysiology and taking care of these patients compared to the past. Dr Jones: That's really helpful context. And I guess that maybe isn't rare when you have a disorder that doesn't have a simple, straightforward biomarker and is complex in terms of the tests you need to do to support the diagnosis, and the treatment itself is somewhat invasive. So, when you talk to your patients, Dr Moghekar, and you've established the diagnosis and have recommended them for CSF diversion, what do you tell them? And the reason I ask is that you mentioned before we started recording, you had a patient who had a shunt placed and responded well, but continued to respond over time. Tell us a little bit more about what our patients can expect if they do have CSF diversion? Dr Moghekar: When we do the spinal tap and they meet our criteria for improvement and they go on to have a shunt, we tell them that we expect gait improvement definitely, but cognitive improvement may not happen in everyone depending on what time, you know, they showed up for their assessment and intervention. But we definitely expect gait improvement. And we tell them that the minimum gait improvement we can expect is the same degree of improvement they had after their large-volume lumbar puncture, but it can be even more. And as the brain remodels, as the hydrodynamics adapt to these shunts… so, we have patients who continue to improve one year, two years, and even three years into the course of the intervention. So, we're, you know, hopeful. At the same time, we want to be realistic. This is the same population that's at risk for developing neurodegenerative disorders related to aging. So not a small fraction of our patients will also have Alzheimer's disease, for example, or go on to develop Lewy body dementia. And it's the role of the neurologist to pick up on these comorbid conditions. And that's why it's important for us to keep following these patients and not leave them just to the neurosurgeon to follow up. Dr Jones: And what a great note to end on, Dr Moghekar. And again, I want to thank you for joining us, and thank you for such a wonderful discussion and such a fantastic article on the clinical diagnosis of normal pressure hydrocephalus. I learned a lot reading the article, and I learned a lot more today just in the conversation with you. So, thank you for being with us. Dr Moghekar: Happy to do that, Dr Jones. It was a pleasure. Dr Jones: Again, we've been speaking with Dr Abhay Moghekar, author of a wonderful article on the clinical features and diagnosis of NPH in Continuum's first-ever issue dedicated to disorders of CSF dynamics. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

We're joined by Dr Atif Magbool at Sidra Medicine who talks to us about the immense challenges and efforts in providing mental healthcare to children and women in crisis-affected areas. Dr Magbool shares his journey into pediatric psychiatry – primarily influenced by early experiences in Sudan – and discusses the significant differences between child and adult psychiatry. The conversation explores the Gaza Patient Program initiated by Sidra Medicine, which offers comprehensive medical, surgical, and psychological care to children affected by the ongoing genocide in Gaza. Dr Magbool also touches upon the remarkable resilience observed in children survivors, the continuous trauma faced by Palestinian children, and the critical need for mental health support during and after war. The dialogue sheds light on the importance of providing a safe and supportive environment for affected children and the broader impact of war on the mental health sector in crisis zones.This episode is in collaboration with Qatar Foundation. 00:00 Introduction01:29 Dr Magbool's Journey into Psychiatry04:32 Understanding Pediatric Psychiatry06:47 The Gaza Patient Program18:42 Challenges in Palestinian Healthcare20:49 Personal Reflections and Emotional Impact30:39 Support for Women in Crisis35:36 Call to Action Dr Atif Magbool is the Lead Consultant for the Inpatient Pediatrics Beds Under Psychiatric Coverage (PBUPC) team and a member of the CAMHS outpatient services at Sidra Medicine. He earned his MBBS from Omdurman University in Sudan and completed his psychiatric training in Ireland, obtaining his MRCPsych in 2012. He later specialized in Child and Adolescent Psychiatry in Scotland, receiving his CCT before working as a consultant there. He also holds diplomas in Clinical Psychiatry and Health Services Management and has extensive experience in managing a wide range of psychiatric and behavioral disorders in children and adolescents across inpatient, outpatient, and day hospital settings. He is also active in medical education and is fluent in Arabic and English, with proficiency in Serbo-Croatian. Hosted by: Mikey Muhanna

Neurological disorders are rising, yet awareness remains alarmingly low. Join us for a compelling conversation with Dr. S. Naresh Kumar, a distinguished neurologist (MBBS, DNB - General Medicine, DM - Neurology), as he breaks down the importance of early detection, prevention, and public education. From strokes to migraines, neurological health touches every life. Hosted by Suhasini, this episode will empower you with insights that matter. Don't miss this special interview on Spotify & Apple Podcast, only on TALRadio.Host : SuhasiniGuest : Dr.S. Naresh Kumar, a distinguished neurologist #TALRadioEnglish #NeurologicalAwareness #BrainHealthMatters #TALHospitals #DrNareshKumar #NeurologyTalks #NeuroCare #PreventNeurologicalDisorders #HealthEducation #TALRadioSpecial #SuhasiniTalks #KnowYourBrain #MedicalAwareness #TouchALife #TALRadio

The vital role of the humanities in shaping empathetic communication skills and critical-minded healthcare professionals is explored today with our guest, P. Ravi Shankar, MBBS, MD. Dr. Shankar, MBBS, MD, currently serves as faculty and program coordinator at the IMU Centre for Education in Kuala Lumpur, Malaysia. He is a Foundation for Advancement of International Medical Education and Research (FAIMER) Institutes Scholar and a prolific researcher. Read more: http://facultyfactory.org/ravi-shankar 

Send us a textIn this episode, Dr. Sciarretta speaks with Dr. Muhammad Mohiuddin, a surgeon who specializes in cardiac xenotransplantation (replacing failing human hearts with pig hearts). Listen to hear more about Dr. Mohiuddin's journey, the ethical and structural issues his work presents, and the moments in which his decades of revolutionary work have come to fruition. Support the showIf you enjoyed this episode please give us a five-star rating and consider donating. Your generosity helps our shoe-string budget and allows us to continue producing high-quality content. Click here to donate.

Get ready for an insightful conversation with Dr. K. Amer Khan, Consultant Intensivist and General Pediatrician, as he takes us behind the scenes of pediatric critical care. With an MBBS, MD in Pediatrics, and a Fellowship in Pediatric Critical Care (IDPCCM), Dr. Khan brings over 6 years of hands-on experience from the Pediatric ICU. In this special interview hosted by Suhasini, we explore the clinical challenges, ethical decisions, and emotional resilience required in saving young lives. Catch this insightful episode on TALRadio English on Spotify and Apple Podcast!Host : SuhasiniGuest : Dr.K.Amer Khan#TALRadioEnglish #TALHospitals #DrAmerKhan #PediatricCare #PICUInsights #CriticalCareHeroes #InsideThePICU #ChildHealthMatters #MedicalStories #HealthcareWithHeart #PediatricIntensivist #DoctorDiaries #EthicsInMedicine #TouchALife #TALRadio

The Central government recently proposed starting an integrated course – MBBS and Ayurveda medicine, at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) in Puducherry. This proposed move has evoked a strong response from the Indian Medical Association who has said this unscientific mixing of various systems of medicine will benefit neither doctors, nor patients. This is not the first move to mix traditional and modern systems of medicine in India – other such measures for instance, have included proposals to allow traditional medical practitioners to prescribe modern medicine after a short course. What are the risks of mixing alternative systems of medicine with the MBBS course? Is there a benefit to integrated systems and if so, how should these be brought in? Has any other country managed to successfully combine alternative systems with modern, evidence based medicine? Guest: Rajeev Jayadevan is the Chairman, Research Cell, Kerala State IMA, Past President, IMA Cochin Host: Zubeda Hamid Edited by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)01245-7/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): T. Yamaguchi: Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc., Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim L. Segan: Nothing to disclose.

Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Cleveland, OH What's changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don't miss this dynamic conversation packed with expertise and hope for the future of AML!

Raisa Amiruddin, MBBS, brings to you a brand-new podcast series delving into the fascinating world of pediatric imaging to empower radiologists everywhere to provide the best possible care for our youngest patients. 

Prashanthan Sanders, MBBS, PhD, FHRS, University of Adelaide is joined by Jenish Shroff, MBBS, MD, Australian National University, and Pugazhendhi Vijayaraman, MD, FHRS, Geisinger Heart Institute, to discuss this first-in-human feasibility study evaluated a novel helix-based leadless pacemaker (LPCSP) designed to achieve left bundle branch area pacing (LBBAP), a capability current LPs lack. The device was temporarily implanted via the internal jugular vein into the interventricular septum in 14 patients, with successful implantation in 10. Electrical performance metrics, including pacing threshold, R-wave amplitude, and impedance, were within acceptable clinical ranges. LBBAP capture was achieved in 5 patients, with no serious device-related adverse events in 85.7% of cases. The study supports the acute safety and feasibility of LPCSP for conduction system pacing.    https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02378-1/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): P. Vijayaraman: Honoraria/Speaking/Consulting: Biotronik, Boston Scientific, Abbott Medical, Medtronic, Inc. Research (Contracted Grants for PIs and Named Investigators only): Medtronic Fellowship Support: Medtronic J. Shroff: Nothing to disclose.

JACC's June 10 issue, focusing on the ACS guideline, features a series of videos with unique perspectives. In this video, JACC: Executive Associate Editor Karthik Murugiah, MBBS, MHS, FACC, introduces his paper discussing the guideline's reliance on four landmark RCTs in AMI-CS. Several sweeping changes in recommendations for MCS use have been codified that should influence practice and improve care for these high-risk patients. While IABP use is expected to decrease, use of mAFP is likely to increase but should be judicious, with caution against overgeneralizing given the narrow selection criteria of DanGer Shock. Evaluating real-world practice patterns and outcomes of patients with AMI-CS based on these recommendations will be paramount.

In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP,... The post Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease appeared first on VJHemOnc.

Beans are a staple in many cuisines around the world. In this episode of the Food as Medicine series, Dr. Parikh interviews Dr. Ruchir Paladiya, a third year medicine resident at the University of Connecticut. Dr. Paladiya details the various nutritional benefits of beans and how you can incorporate them into your diet. 

This World Shared Practice Forum Podcast episode features a discussion on the article "Building Global Collaborative Research Networks in Pediatric Critical Care: A Roadmap," published in Lancet Child and Adolescent Health in February 2025. The conversation, led by Dr. Jeff Burns with guests Professor Luregn Schlapbach and Professor Padmanabhan Ramnarayan, explores the challenges and strategies for creating effective global research networks in pediatric critical care. The speakers highlight the importance of collaboration, the need for a robust evidence base, and the potential of large data models to drive the future of precision medicine and improve patient outcomes. LEARNING OBJECTIVES - Understand the current landscape and challenges of pediatric critical care research - Identify the key components and benefits of global collaborative research networks - Learn about the action plans and goals for advancing global pediatric critical care research AUTHORS Luregn Schlapbach, MD, PhD, Prof, FCICM Head, Department of Intensive Care and Neonatology University Children's Hospital in Zurich, Switzerland Padmanabhan "Ram" Ramnarayan, MBBS, MD, FRCPCH, FFICM Professor of Paediatric Critical Care Imperial College London Jeffrey Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: May 26, 2025. ARTICLE REFERENCED Schlapbach LJ, Ramnarayan P, Gibbons KS, et al. Building global collaborative research networks in paediatric critical care: a roadmap. Lancet Child Adolesc Health. 2025;9(2):138-150. doi:10.1016/S2352-4642(24)00303-1 TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/7hptjhbmtkv8sqx7m86934/202505_WSP_Schlapbach_and_Ramnarayan_Transcript-3864x5000-258ba60.pdf Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Schlapbach LJ, Ramnarayan P, Burns JP. Building Global Pediatric Research Networks. 05/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/building-global-pediatric-research-networks-by-l-schlapbach-p-ramnarayan-openpediatrics.

In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology's hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn't just helpful—it's lifesaving.  

Trilokraj Tejasvi, MD, MBBS interviewed by Brad P. Glick, DO, MPH, FAAD

In this episode, host Shikha Jain, MD, speaks with Abiola Ibraheem, MD, about the role culture plays in improving global oncology, launching the Best of ASCO in Africa and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Ibraheem 1:42 •    The interview 3:02 •    How did you get where you are today?  3:28 •    Can you tell me more about Aortic Africa and your role within the organization? 5:41 •    What are some challenges you have encountered in doing this work, both locally and internationally? 7:33 •    How have you navigated the nuances of global oncology in other countries?  9:51 •    Did you get any pushback when you decided to create these global relationships and inroads? How did you navigate receiving different perspectives on your work? 12:10 •    What are you hoping to achieve with these efforts in global oncology? 16:28 •    Where did the idea for a Best of ASCO Africa come from, and what do you hope to achieve with the event? 17:41 •    Jain and Ibraheem on the importance of providing other countries with tools to implement and drive global change. 22:54 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 27:29 •    How to contact Ibraheem 28:09 •    Thanks for listening 29:07 Abiola Ibraheem, MD, is a board-certified medical oncologist and assistant professor at the University of Illinois Chicago. Her journey in medicine began in Nigeria, where she earned her MBBS degree from Olabisi Onabanjo University. She then completed her internal medicine residency at Morehouse School of Medicine, focusing on racial health care disparities. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ibraheem can be reached via email at abiolai@uic.edu. Learn more about Best of ASCO Africa, as well as how to sign up for in-person or virtual attendance, happening June 27 & 28 in Addis Abba, Ethiopia. Disclosures: Jain and Ibraheem report no relevant financial disclosures. 

In today's episode, we spoke with Shubham Pant, MD, MBBS, and Professor Timothy Elliott, about ongoing research with cancer vaccines. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. Dr Elliott is the Kidani Professor of Immuno-oncology in the Nuffield Department of Medicine at the University of Oxford in the United Kingdom. In our exclusive interview, Pant and Elliott discussed the current landscape of vaccines for cancer treatment, ongoing research seeking to extend the benefits of vaccines as cancer management and prevention strategies, and what the future may hold.

The World Federation of Pediatric Intensive & Critical Care Societies (WFPICCS), in collaboration with OPENPediatrics, recognizes World PICU Awareness Week 2025. This initiative aims to raise global awareness about the importance of PICUs and critical care wards worldwide, emphasizing how healthcare professionals in these units, regardless of resource setting, are driving change. From frugal innovations to digital transformation, this episode highlights how pediatric intensive care is evolving across Asia. Hear from experts in Bangladesh, India, and Indonesia as they share how low-cost technologies, telemedicine, and integrated referral systems are improving outcomes for critically ill children even in the most remote settings. Discover how resilience and resourcefulness are driving change across the region. HOST Arun Bansal, MD, FCCM, FRCPCH Professor in Pediatric Critical Care at PGIMER Chandigarh, India and Chairperson of Pediatric Intensive Care Chapter of India GUESTS Mohammod Joyaber Chisti, MBBS, MMed (Paediatrics), PhD Professor of Pediatrics at icddr,b, Bangladesh Renowned for pioneering low-cost respiratory support technologies like bubble CPAP. Jayashree Muralidharan, MBBS MD Pediatrics FIAP FICCM Head of Pediatric Critical Care at PGIMER, Chandigarh, India A leader in intensive care in India. She had helped in developing and integrating digital health systems into PICU workflows using TelePICU. She also helped in developing a PICU Referral App Kurniawan Taufiq Kadafi, Sp.A(K) Chief of Pediatric Emergency Services, Indonesia, An expert on remote and interfacility pediatric transport across Indonesia's archipelago. DATE Initial publication date: May 7, 2025. TRANSCRIPTS English - https://cdn.bfldr.com/D6LGWP8S/at/k7x72vx63hnbvwx6wpwc4xnt/WPAW-25_Asia_Final_English.pdf Spanish - https://cdn.bfldr.com/D6LGWP8S/at/qxkcv5b23xs49tj6z6w6np/WPAW-25_Asia_Final_Spanish.pdf French - https://cdn.bfldr.com/D6LGWP8S/at/v463w7zbhbbpfbbmj8qf8b/WPAW-25_Asia_Final_French.pdf Portuguese - https://cdn.bfldr.com/D6LGWP8S/at/p377fk7m84xmppk9hx6bbq6/WPAW-25_Asia_Final_Portuguese.pdf Italian - https://cdn.bfldr.com/D6LGWP8S/at/gxbshfgg7xcm7rfpx3p5n4vm/WPAW-25_Asia_Final_Italian.pdf German - https://cdn.bfldr.com/D6LGWP8S/at/4px7mgpbf65rbb8n8vv2sjr/WPAW-25_Asia_Final_German.pdf Arabic - https://cdn.bfldr.com/D6LGWP8S/at/64vtqntqj7v99j4ztc2pk5n3/WPAW-25_Asia_Final_Arabic.pdf Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access, thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu

The World Federation of Pediatric Intensive & Critical Care Societies (WFPICCS), in collaboration with OPENPediatrics, recognizes World PICU Awareness Week 2025. This initiative aims to raise global awareness about the importance of PICUs and critical care wards worldwide, emphasizing how healthcare professionals in these units, regardless of resource setting, are driving change. From AI-driven sepsis screening to innovative non-invasive ventilation protocols, this episode delves into the transformative impact of technology and collaboration in pediatric intensive care across the Middle East. Join us as we hear from leading experts who are pioneering data-driven approaches and creative solutions to improve patient outcomes in resource-limited settings. Discover how these advancements are shaping the future of pediatric care in the region HOST Manu Somasundaram Sundaram, MBBS, MD (India), FRCPCH, CPHQ, MBA. Consultant PICU and Medical Director Quality, SIDRA Medicine , Doha, Qatar Assistant Professor , Weill Cornell Medicine - Qatar GUESTS Omar Al Dafaei, MD Consultant PICU Royal Hospital Muscat, Oman Kholoud Said, MD, MRCPCH Consultant –Pediatric ICU, Royal Hospital Muscat, Oman AbdulRahman Zayed Saad AlDaithan, MD Senior Specialist, Pediatric Intensive Care Unit Pediatrics Division General Ahmadi Hospital, Kuwait Oil Company (KOC) Al Ahmadi Area, Kuwait DATE Initial publication date: May 5, 2025. TRANSCRIPTS English - https://cdn.bfldr.com/D6LGWP8S/at/rnkk777mrhwhq82w78hm54j4/WPAW-25_Middle_East_Final_English.pages Spanish - https://cdn.bfldr.com/D6LGWP8S/at/q37ww33767cvm527g3t92w5p/WPAW-25_Middle_East_Final_Spanish.pdf French - https://cdn.bfldr.com/D6LGWP8S/at/b58j8mpc4xwpm9mwf537hp/WPAW-25_Middle_East_Final_French.pdf Portuguese - https://cdn.bfldr.com/D6LGWP8S/at/7h4r8xg937364bbzbms9w9/WPAW-25_Middle_East_Final_Portuguese.pdf Italian - https://cdn.bfldr.com/D6LGWP8S/at/fsf97qrks969v9q9spbw9n/WPAW-25_Middle_East_Final_Italian.pdf German - https://cdn.bfldr.com/D6LGWP8S/at/56f5rhgws7ns94r6mgh9z/WPAW-25_Middle_East_Final_German.pdf Arabic - https://cdn.bfldr.com/D6LGWP8S/at/46j3wgv359br2fx6j399xtgk/WPAW-25_Middle_East_Final_Arabic.pdf Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access, thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu

Join host Prashanthan Sanders, MBBS, PhD, FHRS, and episode guests Jason G. Andrade, MD, FHRS, and Melanie Gunawardene, MD, as they discuss Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. This discussion was recorded in person at EHRA 2025 in Vienna, Austria. The article under discussion was presented at EHRA 2025 and simultaneously published in the New England Journal of Medicine.   https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2502280   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical   Contributor Disclosure(s): M. Gunawrdene: Honoraria/Speaking/Consulting: Farapulse, Abbott Medical, Boston Scientific, Medtronic, Biotronik, Luma Vision, Bristol Myers Squibb J. Andrade: Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Inc., Biosense Webster, Inc.

Wondering why your performance plateaus despite doing all the “right” things? Dr. Mark Atkinson joins Nick Urban to lay out the difference between short-term fixes & long-term bioharmonized health. We'll be covering nervous system regulation, flow states without substances, stress alchemy, & what high performers miss when they only focus on physical optimization. In this episode, get actionable strategies to rewire your system from the inside out Meet our guest Dr. Mark Atkinson, MBBS, BSc (Hons), FRSPH is a globally respected integrative & functional medicine doctor, master coach, and human potential expert. He co-founded the UK's first professional training in integrative medicine and served as the former medical director of Bulletproof Dr. Atkinson is co-director of Optimal Mind International and the creator of Human Potential Coaching, through which he has trained over 850 coaches. He also leads the Optimal Health, Longevity & Biohacking Certification Program, equipping professionals to teach personalized health, energy, and longevity strategies Thank you to our partners Outliyr Biohacker's Peak Performance Shop: get exclusive discounts on cutting-edge health, wellness, & performance gear Ultimate Health Optimization Deals: a roundup article of all the best current deals on technology, supplements, systems and more Gain mental clarity, energy, motivation, and focus with the FREE Outliyr Nootropics Mini-Course The simple, guided, and actionable Outliyr Longevity Challenge helps you unlock your longevity potential, slow biological aging, and maximize your healthspan Key takeaways Shift mood, energy & focus instantly without supplements or drugs. Use your mind instead Biohacking evolves into bioharmony by balancing mind, emotions & relationships When routines stop working, inner growth & emotional honesty break health plateaus Joy & contentment often come from releasing internal stress, not chasing achievements Saying “welcome” to all thoughts & feelings keeps the nervous system calm & connected Quiet racing thoughts by practicing presence & the inner smile technique Visualizing a smile from your heart shifts mood, eases anxiety & boosts calm Let emotions flow. Honest expression prevents stress buildup & supports lasting health True growth happens when you let go of control & become more attuned to what matters The Optimal Health, Longevity & Biohacking Program offers real results for all levels Episode Highlights 7:14 The World of "Biohacking 3.0" 16:46 The Complete & Integrated Health Model 24:11 Core Practices for Mind Mastery & Self-Regulation 41:41 Relationship Between Emotional Mastery & Flow States 59:57 The New Program Designed For Coaches & Individuals Links Watch it on YouTube: https://youtu.be/gOeDZXqRWoI  Full episode show notes: mindbodypeak.com/206 Connect with Nick on social media Instagram Twitter YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick

The incidence of invasive group A streptococcal infections has risen in the US. Similar observations have been reported in other parts of the world. Authors Joshua Osowicki, MBBS, PhD, of Murdoch Children's Research Institute and Theresa L. Lamagni, MSc, PhD, of the United Kingdom Health Security Agency join JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss the public health challenge posed by group A strep. Related Content: Invasive Group A Streptococcal Disease in the US Invasive Group A Streptococcal Infections in 10 US States

Join JACC Associate Editor Khurram Nasir, MBBS, FACC, and author Rohan Khera, MD, FACC, as they discuss the latest study on tirzepatide presented at ACC.25 and published in JACC. Tirzepatide, a dual GIP/GLP-1 receptor agonist, exerts pleiotropic effects on cardiometabolic health. This study evaluated its efficacy in improving cardiometabolic outcomes in individuals with T2D. An individual participant data meta-analysis was conducted, pooling data from seven Phase 3 RCTs comparing tirzepatide with placebo or standard antihyperglycemic agents. The study outcomes included cardiometabolic components of metabolic syndrome (MetS), elevated BMI, and MetS. Tirzepatide significantly reduced the odds of these abnormalities and effectively resolved MetS, with superior efficacy observed in younger individuals and those not on baseline SGLT2is. These findings support the potential of tirzepatide to improve cardiometabolic health in T2D.

JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further development of AZD0780 as part of a simple, oral regimen for lowering LDL-C beyond that achieved with statin therapy.